CYNAPSUS

Cynapsus is a specialty central nervous system, or CNS, pharmaceutical company developing a fast-acting, easy-to-use, sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD). The Company successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a "turning ON" medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus has..

Also known as: Cynapsus Therapeutics, Cynapsus Therapeutics Inc.

Primary location: Toronto Canada